The investigation by a law firm focuses on whether certain statements regarding the 3.25% convertible senior notes due 2023 were false and misleading. Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's lead product candidate, Ocaliva (obeticholic acid, or OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid, that selectively binds to and activates the farnesoid X receptor, or FXR. On May 31, 2016, Intercept announced that the U.S. Food and Drug Administration ("FDA") had approved Ocaliva for the treatment of patients with primary biliary cholangitis ("PBC").

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced in June 2016 the pricing of its previously announced underwritten public offering of $400 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes).

On September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva (obeticholic acid), the Company's treatment for primary biliary cholangitis ("PBC"), advising them that the drug has been tied to liver injuries and death among patients suffering from PBC.

Those who purchased Intercept Pharmaceuticals Inc (NASDAQ:ICPT) 3.25% convertible senior notes due 2023 have certain options and should contact the Shareholders Foundation.